-- China Stocks: Gemdale, Poly Real Estate, Shanghai Pharma
-- B y   B l o o m b e r g   N e w s
-- 2012-05-23T08:27:55Z
-- http://www.bloomberg.com/news/2012-05-23/china-stocks-gemdale-poly-real-estate-shanghai-pharma.html
Shares of the following companies had
 unusual  moves in  China  trading. Stock symbols are in parentheses
as of the close.  The  Shanghai Composite Index (SHCOMP) , which tracks the bigger of
China’s stock exchanges, fell 9.87 points, or 0.4 percent, to
2,363.44. The  CSI 300 Index (SHSZ300)  declined 0.4 percent to 2,616.87.  Property stocks:  Poly Real Estate Group Co. (600048)  (600048 CH),
China’s second-largest developer by market value, gained 1.5
percent to 13.61  yuan .  Gemdale Corp. (600383)  (600383 CH), the fourth
largest, advanced 3.4 percent to 6.63 yuan. RiseSun Real Estate
Development Co. (002146 CH) rose 3.5 percent to 11.70 yuan.  The real estate market may be supported by strong demand,
the China Securities Journal reported today, citing unidentified
people. Property curbs have stabilized, the newspaper said.  Shanghai Pharmaceuticals Holding Co. (601607)  (601607 CH), China’s
second-largest drug distributor, tumbled by the maximum 10
percent to 10.75 yuan. The company is under investigation from
the China Securities Regulatory Commission and the Hong Kong
Stock Exchange for suspected financial fraud involving two
acquisitions earlier this year, the 21st Century Business Herald
cited an unidentified company executive as saying.  Lu Di, an official in Shanghai Pharma’s board office,
declined to comment when contacted by phone by Bloomberg News.
Scott Sapp, a spokesman for the Hong Kong exchange, declined to
comment. An official at the China Securities Regulatory
Commission’s news office, who asked not to be identified because
of the agency’s rules, said he wasn’t immediately able to
confirm if the regulator was investigating Shanghai Pharma.  --Zhang Shidong. Editor: Allen Wan  To contact Bloomberg News staff for this story:
Zhang Shidong in Shanghai at 
 szhang5@bloomberg.net   To contact the editor responsible for this story:
Darren Boey at   dboey@bloomberg.net  